Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL1061968

Cn1c(=O)c2c(OCC3CCCO3)c(C(=O)N3CCN(c4ccccn4)CC3)sc2c2ccccc21.O=C(O)C(F)(F)F

nearest known ligand 0.45

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 4/20 0.45
KDM4E B2RXH2 4/20 0.45
ALDH1A1 P00352 4/20 0.45
TSHR P16473 3/20 0.45
ALOX15 P16050 1/20 0.45
MAPT P10636 3/20 0.42
GAA P10253 1/20 0.42
HPGD P15428 1/20 0.42
MAPK1 P28482 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
KMT2A Q03164 5/20 0.41
MEN1 O00255 3/20 0.41
HTT P42858 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
PKM P14618 1/20 0.39
LMNA P02545 2/20 0.39
DPP4 P27487 1/20 0.37
RAB9A P51151 1/20 0.37
AXL P30530 1/20 0.37
NOD2 Q9HC29 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10314422 0.96 HSD17B10 (0.48) HSD17B10KDM4EALDH1A1TSHRALOX15
Trifluoroacetic Acid SCHEMBL1057967 0.90 KDM4E (0.42) HSD17B10KDM4EALDH1A1GAAHPGD
Trifluoroacetic Acid SCHEMBL1062400 0.87 HSD17B10 (0.49) HSD17B10KDM4EALDH1A1TSHRALOX15
Trifluoroacetic Acid SCHEMBL1061223 0.86 HSD17B10 (0.48) HSD17B10KDM4EALDH1A1TSHRALOX15
Trifluoroacetic Acid SCHEMBL1061372 0.86 HSD17B10 (0.45) HSD17B10KDM4EALDH1A1TSHRALOX15
SCHEMBL10314419 0.85 KDM4E (0.44) HSD17B10KDM4EALDH1A1MAPTGAA
Trifluoroacetic Acid SCHEMBL1060551 0.85 HSD17B10 (0.47) HSD17B10KDM4EALDH1A1TSHRALOX15
SCHEMBL1062606 0.85 KDM4E (0.45) HSD17B10KDM4EALDH1A1TSHRMAPT
SCHEMBL1058581 0.83 KDM4E (0.43) HSD17B10KDM4EALDH1A1MAPTGAA
SCHEMBL10314356 0.82 HSD17B10 (0.53) HSD17B10KDM4EALDH1A1TSHRALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2247588-B1 FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2016-04-13 EP disclosed
US-8399449-B2 Fused heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-03-19 US disclosed
US-8217176-B2 Fused heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-07-10 US disclosed
US-20110003788-A1 FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-01-06 US disclosed
US-20090227561-A1 FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-09-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003788-A1 FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF SMO, NR1H2, NR1H4 HSD17B10 256/4885KDM4E 528/4885ALDH1A1 745/4885
US-20090227561-A1 FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF SMO, NR1H2, NR1H4 HSD17B10 222/4885KDM4E 464/4885ALDH1A1 776/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.